Sulindac (HLX-0201), dose strength 1 ( DrugBank: Sulindac )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 206 | Fragile X syndrome | 1 |
206. Fragile X syndrome
Clinical trials : 108 / Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04823052 (ClinicalTrials.gov) | May 25, 2022 | 24/3/2021 | Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40 | A Phase 2, Placebo-controlled, Adaptive Design Study to Explore the Safety and Efficacy of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) and Possible Other Treatments in Adolescent and Adult Males With Fragile X Syndrome (FXS) | Fragile X Syndrome | Drug: Sulindac (HLX-0201), dose strength 1;Drug: Sulindac (HLX-0201), dose strength 2;Drug: Placebo;Drug: Gaboxadol (HLX-0206) | Healx Limited | NULL | Withdrawn | 13 Years | 40 Years | Male | 0 | Phase 2 | United States;Australia |